RESUMO
AIM: To determine whether the structural and functional diversities of naturally occurring antibodies to the Thomsen - Friedenreich (TF) antigen may be of diagnostic and prognostic value in colon cancer. MATERIALS AND METHODS: Serum samples were taken from patients with colon cancer (n = 94) and healthy controls (n = 64). The level of TF-specific antibody isotypes and their sialylation were determined using ELISA and lectin-ELISA with synthetic TF-polyacrylamide conjugate as an antigen and a sialic acid-specific Sambucus nigra agglutinin (SNA). The avidity was determined using ammonium thiocyanate as a chaotrope. The accuracy of diagnostics was evaluated using the receiver operator characteristic curve analysis and the survival analysis employing the Kaplan - Meier method. RESULTS: Compared to healthy controls, patients with colon cancer exhibited a lower level of anti-TF IgG antibodies, significantly lower ratios of TF-specific IgG/IgM and IgG/IgA, an increased SNA reactivity of anti-TF antibodies, mostly on account of IgG, and a lower avidity of TF-specific antibodies, especially their SNA-reactive subset. An increased SNA reactivity of anti-TF IgG was observed already at the early stages of cancer (p = 0.0004). The decrease of the ratio of IgG/IgM and IgG/IgA showed a good accuracy of diagnostics with about 60% sensitivity at 90% specificity. A similar potential was found for the SNA binding/IgG level index. The high level of TF-specific IgA antibodies was associated with a lower survival rate (hazard ratio = 0.34). CONCLUSION: This is the first report ever on the colon cancer-related signatures of anti-TF antibody diversity which show diagnostic potential, including in early cancer, and prognostic value. The hypersialylation of TF-specific antibodies appeared to be a common phenomenon in cancer. The signatures may be used as non-invasive antibody-based markers for colon cancer.
Assuntos
Anticorpos/imunologia , Biomarcadores Tumorais/imunologia , Neoplasias do Colo/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Diversidade de Anticorpos , Antígenos Glicosídicos Associados a Tumores/imunologia , Área Sob a Curva , Neoplasias do Colo/diagnóstico , Neoplasias do Colo/mortalidade , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Curva ROC , Adulto JovemRESUMO
UNLABELLED: The elevated anti-GalNAcß IgG level of serum was shown to be associated with the significantly better survival of patients with gastrointestinal cancer. AIM: To characterize the specificity of IgG antibodies to GalNAcß-terminated glycans of long-term gastric cancer survivors. METHODS: Serum antibodies and affinity-isolated antibodies were analysed by the indirect and competitive ELISA using glycan-polyacrylamide (PAA) conjugates as well as by isoelectric focusing and Western blotting. RESULTS: In the serum probes, a partial cross-reactivity of antibodies to GalNAcß, GalNAcß1-3Galß (X2di), GalNAcß1-3GalNAcß (PFdi) and GlcNAcß was observed. The isolated anti-GalNAcß IgGs demonstrated the cross-reactivity to the X2di glycan mainly. The affinity of the X2di-PAA to anti-GalNAcß IgGs was 11-21 times lower than that of the GalNAcß-PAA. Anti-X2di and anti-PFdi IgGs demonstrated monoreactivity to their key glycans-PAA used in isolation. The IC50 values of key glycoconjugates ranged from 1 to 5 · 10(-7) M. No polyreactivity of antibodies to the unrelated antigens (ferritin, casein and DNA) was found. The polyclonal or oligoclonal distribution of IgG bands was established and the monoreactivity of antibodies was not associated with the clonal distribution of bands. CONCLUSION: The cross-reactivity of anti-GalNAcß antibodies to X2di and related glycans deserves attention in the clarification of the role of antibodies in cancer progression and enhancement of the prognostic potential in the combined determination of antibody markers.
Assuntos
Galactosiltransferases/biossíntese , Imunoglobulina G/sangue , Proteoglicanas/sangue , Receptores de Fatores de Crescimento Transformadores beta/sangue , Neoplasias Gástricas/sangue , Adulto , Idoso , Anticorpos/sangue , Especificidade de Anticorpos/imunologia , Feminino , Galactosiltransferases/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Proteoglicanas/imunologia , Receptores de Fatores de Crescimento Transformadores beta/imunologia , Neoplasias Gástricas/imunologia , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia , Análise de Sobrevida , SobreviventesRESUMO
UNLABELLED: Serum anti-(GalNAcß) and anti-para-Forssman disaccharide (PF(di), GalNAcß1--3GalNAcß) IgG levels were earlier found to be related to histological grading and progression of gastrointestinal cancer. AIM: To study the relation of serum antibodies level to survival in patients with gastrointestinal cancer. METHODS: The level of anti-GalNAcß, and PF(di) IgG was analysed in the serum of patients with gastric (n = 78) and colorectal (n = 48) cancers in the long-term follow-up using ELISA with polyacrylamide glycoconjugates. Survival rate and hazard ratio (HR) were assessed by the Kaplan -- Meier method and Cox univariate analysis in different patho-morphological groups. RESULTS: Better survival was observed in patients with an increased preoperative level of GalNAcß antibodies. These were the gastrointestinal group in stages II, III or tumors T2--4 (n = 90--104, P = 0.007, HR = 0.48--0.49, 95% CI 0.27--0.83, and the group with gastric cancer in stages I, II (n = 49, P = 0.051, HR = 0.39, 95% CI 0.14-1.04). The survival time was significantly longer in the gastrointestinal group in patients whose GalNAcß antibodies level rose in dynamics (stage III or N1--2: p = 0.031--0.039, HR = 0.29--0.31, 95% CI 0.09--1.00). No significant difference in survival of patients was observed in the evaluation of PF(di) antibodies. We suggest that the level of antibodies and its change reflect the enteric microbiota colonization, which may influence cancer progression via different interrelations between microbiota, the tumor and immune system. CONCLUSION: The preoperative level of GalNAcß antibodies and its dynamics may be of prognostic significance for clinical outcome assessment.
Assuntos
Acetilgalactosamina/imunologia , Anticorpos Heterófilos/sangue , Neoplasias Gastrointestinais/imunologia , Neoplasias Gastrointestinais/mortalidade , Idoso , Neoplasias Colorretais/imunologia , Neoplasias Colorretais/mortalidade , Neoplasias Colorretais/patologia , Neoplasias Colorretais/cirurgia , Dissacarídeos/imunologia , Feminino , Seguimentos , Neoplasias Gastrointestinais/patologia , Neoplasias Gastrointestinais/cirurgia , Humanos , Estimativa de Kaplan-Meier , Metástase Linfática/imunologia , Masculino , Pessoa de Meia-Idade , Período Pré-Operatório , Modelos de Riscos ProporcionaisRESUMO
All human immunoglobulins are glycosylated. The changes in IgG glycosylation are associated with autoimmune disorders and pregnancy. Little is known about IgG glycosylation in patients with cancer. A lectin enzyme-linked immunosorbent assay (LELISA) based method was developed for measuring the Concanavalin A - positive IgG in the serum. Its rationale is as follows: PtA was used as a capture agent for binding IgG via the Fc fragment. Then IgG and the ConA-positive glycans on the IgG were detected using an anti-human IgG-F(ab)2 alkaline phosphatase conjugate or biotinylated ConA, respectively. The index ConA binding/total IgG was calculated. Serum samples from patients with gastric carcinoma (n=53) and healthy blood transfusion donors (n=24) were analysed. The protein A-agarose and ConA-sepharose affinity chromatography was applied to the purification of IgG, ConA-positive IgG, and Fab fragments. The LELISA, SDS-PAGE and Western blot methods were used to analyse the purified IgG and Fab fragments. A significantly higher ConA binding to IgG was found in patients with cancer compared to that of blood donors (ConA index = 1.07+/-0.08 (95% CI) and 0.81+/-0.08, respectively; P=0.0002). In donors, a significant correlation between the level of IgG bound to PtA and the ConA binding (r=0.85; p<0.001) was observed. Patients with gastric cancer showed a less pronounced, though significant correlation (r=0.33; P=0.02). Only the Fd fragment of the Fabs derived from both total serum IgG and ConA-positive fraction of IgG contained the ConA-positive glycans. The comparison of the purified IgG and Fab fragments derived from healthy blood donors and patient with gastric cancer showed no difference in either SDS-PAGE, immunoblotting or LELISA pattern. The LELISA is simple, reproducible and suitable for the evaluation of IgG glycosylation changes. The level of ConA positive serum IgG was found to be increased in patients with cancer. No convincing evidence of the presence of asymmetrically glycosylated F(ab)2 fragments was found. A trend towards a better survival of patients with a lower level of the ConA-positive IgG was observed suggesting a possible blocking effect of the latter on tumor immunity.
Assuntos
Concanavalina A/metabolismo , Ensaio de Imunoadsorção Enzimática/métodos , Imunoglobulina G/sangue , Neoplasias Gástricas/imunologia , Idoso , Feminino , Glicosilação , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The soluble E-receptor (SER) of lymphocytes that is related to CD2 was detected in human plasma and serum using immunoelectrophoresis with sheep antiserum. All plasma samples (n=18) demonstrated reactivity with antiserum, whereas the reactivity of the corresponding sera remained low or undetectable. The depletion of SER in clotting is associated with fibrinogen, as shown by crossed-affinity immunoelectrophoresis with antisera to plasma proteins. The SER-associated fibrinogen was purified and analysed by the SDS-polyacrylamide gel electrophoresis and immunoblotting. A band close to 66 kDa was detected with monoclonal antibodies to CD2. The association of CD2 and other soluble receptors with fibrinogen via domains is suggested. It is recommended that the fresh plasma, not serum, should be used to study circulating receptors because coagulation may appreciably diminish their physiological level in blood samples.
Assuntos
Coagulação Sanguínea , Antígenos CD2/sangue , Fibrinogênio/metabolismo , Plaquetas/química , Antígenos CD2/imunologia , Antígenos CD2/isolamento & purificação , Fibrinogênio/imunologia , Fibrinogênio/isolamento & purificação , Humanos , ImunoeletroforeseRESUMO
Many investigators have demonstrated alteration of gastric mucins in H. pylori infected individuals. The inflammatory environment induced by H. pylori leading to aberrant glycosylation of MUC1 and demasking of core peptide MUC1 epitope could enhance immune responses to MUC1. IgG and IgM immune response to MUC1 in patients with gastric cancer (n = 214) chronic gastroduodenal diseases (n = 160) and healthy blood donors (n = 91) was studied with ELISA using bovine serum albumin-MUC1 60-mer peptide as antigen. H. pylori serologic status was evaluated with ELISA and CagA status by immunoblotting. Gastric mucosa histology was scored according to the Sydney system. Compared to H. pylori seronegative individuals, higher levels of IgG antibody to MUC1 were found in H. pylori seropositive patients with benign gastric diseases (p < 0.01) and blood donors (p < 0.03). Higher MUC1 IgG antibody levels were associated with a higher degree of gastric corpus mucosa inflammation in patients with chronic gastroduodenal diseases (p < 0.0025). There was a positive correlation between the levels of anti-H. pylori IgG and MUC1 IgG antibody levels in blood donors (p = 0.03), and in patients with benign diseases (p < 0.0001). In patients with gastric cancer (n = 214) a significantly higher level of anti-MUC1 IgG than in blood donors was observed (p < 0.001) irrespective of H. pylori status or stage of cancer. MUC1 IgM antibody levels were not related to the H. pylori serology. IgG immune response to tumor-associated MUC1 is up regulated in H. pylori infected individuals. This increase is associated with a higher IgG immune response to H. pylori and with a higher degree of gastric mucosa inflammation. High levels of MUC1 IgG antibody irrespective of H. pylori serologic status characterized patients with gastric cancer. The findings suggest that, in some individuals, the H. pylori infection may stimulate immune response to tumor-associated MUC1 peptide antigen thus modulating tumor immunity.
Assuntos
Infecções por Helicobacter/imunologia , Helicobacter pylori/imunologia , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Mucina-1/imunologia , Gastropatias/imunologia , Neoplasias Gástricas/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/imunologia , Antígenos de Bactérias/metabolismo , Proteínas de Bactérias/imunologia , Proteínas de Bactérias/metabolismo , Doença Crônica , Feminino , Mucosa Gástrica/imunologia , Mucosa Gástrica/microbiologia , Gastrite/imunologia , Gastrite/microbiologia , Infecções por Helicobacter/microbiologia , Helicobacter pylori/patogenicidade , Humanos , Masculino , Pessoa de Meia-Idade , Mucina-1/metabolismo , Gastropatias/microbiologia , Neoplasias Gástricas/microbiologiaRESUMO
Humoral immune responses to the MUC1 peptide and to MUC1-related Thomsen-Friedenreich (TF) glycotope was investigated in patients with gastric cancer (n = 247), chronic gastroduodenal diseases (n = 199) and in healthy blood donors (n = 100). Data were correlated with disease type, stage of cancer, tumor morphology and survival. MUC1 IgG antibody levels were higher in patients with gastric cancer (p < 0.0001) than in healthy controls. Higher levels of anti-MUC1 IgG were also detected in patients with ulcer of the stomach (p = 0.015) and in atrophic gastritis (p = 0.027). Compared to blood donors, significantly lower levels of anti-TF IgG were found both in the cancer (p = 0.002) and in the benign group (p < 0.0001). At early stages of cancer a positive correlation (p < 0.0001) was found between MUC1 IgG and TF IgG antibody levels. High levels of TF IgG antibodies were significantly associated with a benefit in survival of gastric cancer patients (p = 0.003). A similar though weaker association was observed for patients with high levels of MUC1 IgG antibodies and locoregional disease (stage I-III) (p = 0.037). Thus IgG immune responses to MUC1 are increased in patients with gastric cancer. High levels of either TF IgG or MUC1 IgG antibodies may predict better outcome in surgically treated patients with gastric cancer.
Assuntos
Adenocarcinoma/imunologia , Adenocarcinoma/mortalidade , Anticorpos/imunologia , Antígenos de Neoplasias/imunologia , Mucinas/imunologia , Neoplasias Gástricas/imunologia , Neoplasias Gástricas/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Antineoplásicos/sangue , Antígenos de Neoplasias/sangue , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/imunologia , Estudos de Casos e Controles , Úlcera Duodenal/imunologia , Gastrite Atrófica/imunologia , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Pessoa de Meia-Idade , Mucina-1 , Estadiamento de Neoplasias , Úlcera Gástrica/imunologia , Análise de SobrevidaRESUMO
UNLABELLED: Earlier we found two unusual IgG-antibody specificities to GalNAc beta and GalNAc beta1-3GalNAc beta (para-Forssman disaccharide, PFdi) carbohydrate ligands in human serum. The aim of the study was to evaluate whether elevated antibody levels are related to the progression of gastrointestinal cancer and the histopathological grading. METHODS: Specific IgG levels were tested in 159 patients with gastric cancer, 88 patients with colorectal cancer and 96 blood donors by the ELISA using synthetic polyacrylaamide (PAA) conjugates, GalNAc beta-PAA and PFdi-PAA. Biochemical and haematological analyses were performed using automatic equipment. RESULTS: The anti-PFdi IgG levels were significantly higher in patients with gastric and colorectal cancer than in donors: in stages II-IV, P = 0.0002 - 0.04 (U-test). The elevated anti-PFdi IgG level was associated with the advanced gastric cancer: in stages II, III, IV vs stage I (P = 0.004 - 0.06) and in case of the tumor size T2 + T3 vs T1 (stages I, II; P = 0.03). Differences in anti-GalNAc beta IgG level were insignificant. No relation between antibody levels and the regional and distant metastases of gastric or colorectal cancer was found. The lower anti-GalNAc beta IgG level was associated with lower-differentiated carcinomas (P = 0.01 - 0.04). Prolonged postoperative changes in the levels of both antibodies during the follow-up were established. An elevation of both antibody levels in patients with gastrointestinal cancer was revealed after a surgical removal of G3-tumors (P = 0.003 - 0.01). The anti-PFdi IgG levels correlated with the levels of the C-reactive protein: r = 0.50, P = 0.003. The anti-GalNAc beta IgG levels correlated with the percentage of peripheral blood monocytes: r = 0.42, P = 0.002. CONCLUSION: The association of the anti-PFdi IgG level with cancer progression suggests the implication of antibodies in the pathogenesis of gastrointestinal cancer. Further studies are required to identify natural targets of antibodies, their relation to other diseases, prognostic significance in cancer.
Assuntos
Anticorpos Antineoplásicos/sangue , Antígenos Glicosídicos Associados a Tumores/imunologia , Neoplasias Gastrointestinais/imunologia , Globosídeos/imunologia , Imunoglobulina G/sangue , Adulto , Idoso , Formação de Anticorpos , Especificidade de Anticorpos , Progressão da Doença , Ensaio de Imunoadsorção Enzimática , Feminino , Antígeno de Forssman/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Taxa de SobrevidaRESUMO
AIM: To study the humoral immune response to tumor-associated carbohydrate epitopes (TF, Tn and alphaGal) in patients with breast cancer and healthy donors, the putative impact of the chemotherapy and to evaluate if the level of antibody to these epitopes might be beneficial or detrimental for the patients with breast cancer. MATERIALS AND METHODS: The humoral immune response to TF, Tn and alphaGal was studied in 133 patients with breast cancer, including the patients at stage II-III (n = 44) before and after neoadjuvant chemotherapy (10 patients received cyclophosphamide/methotrexate/fluorouracyl (CMF) chemotherapy regimens, 34 patients received cyclophosphamide/doxorubicin/fluorouracil (CAF)), and in controls (healthy donors and patients with fibroadenoma). Fully synthetic carbohydrate hapten-polyacrylamide conjugates were used as antigens in ELISA for anti-carbohydrate antibody determination. The correlation analysis between the level of anti-carbohydrate antibodies and the stage of cancer, histological grade, expression of TF and alphaGal epitopes in tumor tissue, patient's survival was performed. RESULTS: The level of anti-carbohydrate antibodies varied between individuals with no significant correlation between IgG immune response to the three epitopes. Lower levels of antibodies were observed at advanced stages of cancer. Neoadjuvant chemotherapy stimulated antibody production to Tn and alphaGal epitopes (increase > 50%) in about one third of patients. Immunosuppression, decrease in antibody levels, was observed only in 4.5-13.6% of cases. High levels of TF-antigen specific IgG antibody before surgery were associated with a better survival time of stage II breast cancer patients. CONCLUSION: The widely used regimens of neoadjuvant chemotherapy (such as CMF, CAF) can stimulate the immune response to tumor-associated carbohydrate epitopes in some patients. The high levels of anti-TF antibody before surgery are associated with a better survival of stage II breast cancer patients. This may indicate that the selection of immunopotentiating regimens of neoadjuvant chemotherapy might be beneficial for the host.
Assuntos
Anticorpos Antineoplásicos/análise , Antígenos Glicosídicos Associados a Tumores/imunologia , Neoplasias da Mama/imunologia , Neoplasias da Mama/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Formação de Anticorpos , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Epitopos , Feminino , Fibroadenoma/tratamento farmacológico , Fibroadenoma/imunologia , Fibroadenoma/mortalidade , Fluoruracila/administração & dosagem , Haptenos , Humanos , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Terapia Neoadjuvante , Estadiamento de Neoplasias , Taxa de Sobrevida , Tromboplastina/imunologia , alfa-Galactosidase/imunologiaRESUMO
The Galalpha1-3Galbeta (alphaGal) hapten is xenogeneic for humans; natural anti-alphaGal antibodies are present in human serum. To study the possible abnormal expression of the alphaGal in humans and the pathophysiological role of antibodies, the method of affinity purification of human anti-alphaGal IgG was developed. The specificity of antibodies was evaluated using polyacrylamide (PAA)-based glycoconjugates in direct and competitive enzyme-linked immunosorbent assays (ELISA). The purified antibodies exhibited alphaGal-restricted specificity. The IC50 value for alphaGal-PAA was equal to 4 x 10(-8) M. In a competitive assay, the Galalpha1-3(Fucalpha1-2)Galbeta-PAA (trisaccharide of blood group B) was found to be one hundred times less active inhibitor than alphaGal-PAA. The multivalent alphaGal-PAA was 1100 times more potent an inhibitor than the monovalent spacered alphaGal-saccharide. The antibodies did not show any reactivity to the negatively charged antigens (DNA, human tumor-derived mucins). At a concentration of 2 microg/mL, the antibodies agglutinated rabbit erythrocytes but not hare erythrocytes. The high reactivity of antibodies to the alphaGal-glycosphingolipids of rabbit erythrocytes and the pig kidney was shown by a modified sensitive method of thin-layer chromatography with immunodetection.
Assuntos
Glicoesfingolipídeos/sangue , Haptenos/imunologia , Imunoglobulina G/imunologia , Trissacarídeos/imunologia , Animais , Especificidade de Anticorpos , Dissacarídeos/imunologia , Ensaio de Imunoadsorção Enzimática , Eritrócitos/metabolismo , Glicoconjugados/imunologia , Glicoesfingolipídeos/imunologia , Humanos , Rim/metabolismo , Mucinas/imunologia , Coelhos , SuínosRESUMO
The TF, Tn, and SiaTn glycotopes are frequently expressed in cancer-associated mucins. Antibodies to these glycotopes were found in human serum. A set of polyacrylamide (PAA)--based glycoconjugates was applied to the direct and competitive enzyme-linked immunosorbent assays (ELISA) to characterize the specificity of serum IgG antibodies. The anti-TF, -Tn and -SiaTn IgG were affinity purified from serum of cancer patients and characterized using PAA-conjugates and free saccharides. The anti-TF and -Tn antibodies were shown to be specific. The anti-TF IgG bound both Galbeta1-3GalNAcalpha- and Galbeta1-3GalNAcbeta-PAA, the latter was three-four times more effective inhibitor of antibody binding. The anti-Tn IgG reacted only with GalNAcalpha-PAA. The anti-SiaTn IgG cross-reacted with Tn-PAA but SiaTn-PAA was five-six times more effective inhibitor in a competitive assay. The IC50 values for PAA-conjugates with the corresponding antibodies typically ranged from 2 to 5 x 10(-8) M. The antibodies display a low specificity to mucin-type glycoconjugates in comparison with PAA-conjugates as was shown for mucins isolated from human malignant tumor tissues, ovine submaxillary mucin (OSM) and asialo-OSM. The unusual IgG-antibody specificity to GalNAcbeta and GalNAcbeta1-3GalNAcbeta ligands was found in human serum.
Assuntos
Especificidade de Anticorpos/imunologia , Carboidratos/imunologia , Glicoconjugados/imunologia , Imunoglobulina G/imunologia , Resinas Acrílicas/química , Epitopos/imunologia , Glicoconjugados/química , Humanos , Imunoglobulina G/sangue , Sondas Moleculares , Mucinas/imunologia , Soro/imunologiaRESUMO
A possible association of serum anti-T IgM and IgG antibody levels with Lewis blood-group phenotype was investigated in 168 blood donors and 132 gastric cancer patients using ELISA with synthetic T-disaccharide-polyacrylamide conjugate as antigen. The donors of Le(a-b+) phenotype showed the highest anti-T IgM level irrespective of ABO(H) blood group. A significant decrease in anti-T IgM in serum was observed among cancer patients of Le(a-b+) phenotype: 95% of weak responders versus 17.5% for related groups of donors (p < 10(-6)). In contrast, no significant difference between patients and donors was found for Le(b-) individuals. Thus, a level of natural anti-T antibodies in serum of blood donors and its decrease in patients with gastric cancer are related to Le(a,b) phenotype. This should be taken into account where anti-T antibody level in the serum is used as a tumour marker or for monitoring patients during cancer immunotherapy with mucin-type vaccines.
Assuntos
Antígenos de Neoplasias/imunologia , Antígenos Glicosídicos Associados a Tumores/imunologia , Doadores de Sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Antígenos do Grupo Sanguíneo de Lewis , Neoplasias Gástricas/imunologia , Sistema ABO de Grupos Sanguíneos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fenótipo , Neoplasias Gástricas/sangueRESUMO
IgG immune response to CagA was evaluated by enzyme-linked imunosorbent assay (ELISA) using a recombinant fragment of CagA as antigen in 171 patients with gastric cancer and 298 blood donors to determine whether it could be related to the ABO(H) blood group phenotype, stage of cancer or tumor morphology. The CagA-ELISA showed a good specificity (93.5%) and sensitivity (88.5%) as compared with immunoblotting for blot CagA-negative and -positive donors. The Helicobacter pylori seropositive blood group A donors revealed the lowest proportion (37.6%) of strong responders to CagA: AAssuntos
Sistema ABO de Grupos Sanguíneos
, Anticorpos Antibacterianos/sangue
, Antígenos de Bactérias
, Proteínas de Bactérias/imunologia
, Infecções por Helicobacter/imunologia
, Helicobacter pylori/imunologia
, Neoplasias Gástricas/imunologia
, Adulto
, Idoso
, Doadores de Sangue
, Eletroforese em Gel de Poliacrilamida
, Ensaio de Imunoadsorção Enzimática
, Feminino
, Humanos
, Immunoblotting
, Masculino
, Pessoa de Meia-Idade
, Estadiamento de Neoplasias
, Proteínas Recombinantes/imunologia
, Neoplasias Gástricas/sangue
, Neoplasias Gástricas/patologia
RESUMO
Individuals of the Le(b+)/secretor phenotype revealed a stronger natural immune response to Le(x) and Le(y) epitopes irrespective of Helicobacter pylori serologic status. In contrast, H. pylori-infected Le(b-) type individuals showed a significantly higher proportion of strong responders to Le(x) antigen compared with the H. pylori-uninfected subgroup. The data suggest that the immune response to Lewis type 2 determinants is related to both the H. pylori serologic status and the Le(a,b) phenotype of the host.
Assuntos
Doadores de Sangue , Infecções por Helicobacter/imunologia , Imunoglobulina G/imunologia , Antígenos do Grupo Sanguíneo de Lewis/imunologia , Adulto , Idoso , Ensaio de Imunoadsorção Enzimática , Feminino , Helicobacter pylori/imunologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
OBJECTIVE: To study a possible association of the Helicobacter pylori seroprevalence with ABO(H) and Lewis (a,b) blood group phenotypes in blood donors. DESIGN: A cross-sectional study of blood donors using ABO(H) and Lewis (a,b) blood group phenotype as predictors. METHODS: ABO(H) and Lewis (a,b) blood group phenotyping was performed with monoclonal antibody. The H. pylori immunoglobulin G (IgG) antibody relative activity was evaluated by enzyme-linked immunosorbent assay (ELISA) using acid glycine extract from H. pylori. SUBJECTS: One hundred and fifty-nine randomly selected blood transfusion donors. RESULTS: The individuals with Lewis (a+b-)/non-secretor phenotype showed a significantly higher proportion of the H. pylori-seronegative subjects and a lower IgG immune response to H. pylori antigens as compared with the individuals of Lewis (a-b+)/secretor phenotype. CONCLUSION: The Lewis (a,b) histo-blood group antigens are implicated in the mechanisms of naturally occurring resistance to H. pylori infection.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Anticorpos Antibacterianos/análise , Doadores de Sangue , Infecções por Helicobacter/sangue , Helicobacter pylori/imunologia , Antígenos do Grupo Sanguíneo de Lewis/imunologia , Adolescente , Adulto , Anticorpos Monoclonais , Antígenos de Bactérias/imunologia , Antígenos de Superfície/imunologia , Estudos Transversais , Ensaio de Imunoadsorção Enzimática , Estônia/epidemiologia , Feminino , Humanos , Imunofenotipagem , Masculino , Pessoa de Meia-Idade , Prevalência , Distribuição Aleatória , Componente Secretório/imunologiaRESUMO
The level of IgM antibodies to the Thomsen-Friedenreich hapten (TF) relative to the total IgM level in the blood sera of gastric and breast carcinoma patients and healthy persons was determined using enzyme-linked immunosorbent assay. The following TF glycoconjugates were tested: TF-polyacrylamide (PAA)(with 10 mol.% of TF hapten Gal beta 1-3GalNAc alpha 1-O(CH2)3NH per number of monomeric units in the polyacrylamide), TF-human serum albumin (HSA)(Gal beta 1-3GalNAc alpha 1-O-p-C6H4-HSA containing approximately 15 carbohydrate residues per HSA molecule), asialo-kappa-caseinoglycopeptide, and asialoglycophorin. The total IgM level was determined using antibodies to the mu-chain of human IgM. The statistically significant difference between cancer patients and healthy donors was revealed with two conjugates: TF-PAA and TF-HSA. In the case of TF-PPA, the sensitivity of the assay was 75-83%, and the specificity was 77%. Thus, TF-PAA is the most suitable conjugate for measuring the level of serum anti-TF-IgM antibodies.
Assuntos
Anticorpos/sangue , Antígenos de Neoplasias/sangue , Neoplasias da Mama/diagnóstico , Ensaio de Imunoadsorção Enzimática , Imunoglobulina M/sangue , Neoplasias Gástricas/diagnóstico , Resinas Acrílicas/química , Anticorpos/imunologia , Assialoglicoproteínas/química , Neoplasias da Mama/imunologia , Feminino , Glicoconjugados/sangue , Haptenos/imunologia , Humanos , Albumina Sérica/química , Neoplasias Gástricas/imunologiaRESUMO
Helicobacter pylori infection is considered to be a risk factor for gastric cancer. A high prevalence of H. pylori infection and high gastric-cancer incidence are characteristic of the Estonian population. To evaluate the relationship between these 2 events, we studied the seroprevalence of H. pylori in gastric cancer patients (n = 182) and in healthy blood donors (n = 306). A relative anti-H. pylori IgG antibody activity, as detected by ELISA and immunoblot patterns, was correlated with age, stage of the disease and tumor morphology. A significantly higher H. pylori seroprevalence was found in patients in the early stages of tumor development compared with both advanced cancer patients and controls. No significant difference in H. pylori seroprevalence between patients with the intestinal and diffuse types of tumor growth was observed. A decline in the recognition of putatively cross-reacting (33-66 kDa) antigens was noted in the cancer group. The response to vacuolating toxin-related 85-kDa and CagA 120-kDa protein antigens was not altered and was observed more often in the younger group of cancer patients.
Assuntos
Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/imunologia , Helicobacter pylori/imunologia , Imunoglobulina M/sangue , Neoplasias Gástricas/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Proteínas de Bactérias/imunologia , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Immunoblotting , Masculino , Pessoa de Meia-Idade , Peso Molecular , Estadiamento de Neoplasias , Neoplasias Gástricas/patologiaRESUMO
The TFA is a tumor-associated, blood-group-related glycosidic precursor structure [Gal(beta 1-3)GalNAc]. Its expression in carcinomas is accompanied by a decrease of natural TFA antibodies in serum. The relationship between the ABO(H)-blood-group phenotype and natural anti-TFA immune response in patients with gastric cancer was studied. The level of TFA agglutinins in the sera of patients with gastric cancer and of healthy controls was examined by the hemagglutination of neuraminidase-treated blood-group-O donor erythrocytes. Individuals were classified as weak or strong TFA responders. They were also classified by ABO(H)-blood-group status, age, cancer stage, tumor morphology and level of isohemagglutinins. The proportion of weak TFA responders (WR) in cancer patients was 33, 50, 50 and 20% (for O, A, B and AB blood groups respectively), as compared with 11.7, 14.5, 13.9 and 26.1% for blood-group-related controls. The difference between cancer patients and controls was significant for all blood groups except group AB. Further analysis showed age-dependence in blood-group-O and -B controls, with a high level of WR in the older group. Blood-group-A cancer patients had the greatest and uniform suppression of the level of TFA agglutinins, irrespective of age, cancer stage or tumor morphology, and lower levels of anti-B isohemagglutinins.
Assuntos
Aglutininas/sangue , Anticorpos/sangue , Neoplasias Gástricas/sangue , Sistema ABO de Grupos Sanguíneos , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fenótipo , Neoplasias Gástricas/genéticaRESUMO
BACKGROUND: A low natural humoral immune response to Thomsen-Friedenreich antigen (TFA) is a general phenomenon in patients with cancer, including gastric cancer, and in some premalignant conditions. It has been also shown that Helicobacter pylori infection is associated with increased risk of gastric cancer. The possible link between the TFA immune response and H. pylori infection was investigated. METHODS: Enzyme-linked immunosorbent assay with H. pylori cell surface glycine extract as antigen and microhemagglutination of neuraminidase-treated blood group O donor erythrocytes were used for evaluation of IgG H. pylori antibody and TFA agglutinin levels in sera from patients with gastric cancer (n = 39) or ulcer of the stomach (n = 36) and controls (n = 49). RESULTS: The tendency to an inverse relationship between the two events was found in all groups studied, including cancer. H. pylori-seronegative persons had higher TFA natural antibody titer than the related H. pylori-seropositive groups. When log2 of TFA antibody titer > 4 for strong TFA responders and H. pylori relative antibody activity > 25 for H. pylori-seropositive persons were chosen as cut-off limits, the association was statistically significant (p < 0.02). TFA antibody level was decreased in cancer patients as compared with controls (p < 0.002). No relation to age, stage of the disease, or tumor morphology was noted. CONCLUSION: The data suggest that the TFA natural immune response, which is known to participate in tumor-host relationships, is also involved in H. pylori-host interactions, probably as a natural factor of resistance against H. pylori infection.